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Background
Cervical cancer is the second most common cancer in women with 90% of cervical cancers caused by high-risk HPV strains such as types 16 . However, issues include patient compliance and a lack of efficacy against established HPV infections. This is due to the fact that upon infection, the intracellular location of the virus confers resistance to antibody attack 4 . For this reason, the development of a therapeutic HPV vaccine to treat patients with established HPV infections is clearly an unmet need 5 .
HPV early proteins, particularly E6 and E7 viral genes are candidate target antigens for therapeutic vaccination; responsible for malignant transformation and tumour growth 6 . The E6 and E7 viral proteins disrupt tumour suppressor functions of p53 and the retinoblastoma protein (pRb) respectively 7 . The E6 protein stimulates p53 degradation via cellular ubiquitination, which disrupts the control of cell cycle progression. While the E7 protein disturbs pRb, repressing regulation of replication-associated genes 8 . Several therapeutic vaccine applications for HPV-16 E6 and E7 have been studied in preclinical models over the past two decades [9] [10] [11] [12] , with limited success 13 .
DNA vaccination has become an effective strategy for the development of therapeutics against many types of cancer, including breast, ovarian, prostate 14 , and cervical carcinoma 15 .
Numerous DNA vaccines directed against either HPV16 E6 or E7 have been tested with promising results in murine models [16] [17] [18] [19] [20] . However, successful implementation of DNA-based vaccination strategies requires a robust gene delivery vehicle capable of penetrating plasma membranes, protecting the nucleic acid cargo from intercellular degradation and ensuring the delivery to the nucleus of the target cell 21 . There is also a need to deliver the DNA to antigen presenting cells (APCs), so that the intracellular antigens are processed through both the MHC class I and II presentation pathways, ensuring a full complement of cellular and humoral immune responses 22 . We have bioengineered a novel 30 amino acid cationic peptide delivery sequences, termed RALA. RALA consists of arginine/alanine/leucine/alanine repeats, interacts with anionic nucleic acids via electrostatic interaction to form nanoscale cationic particles. Moreover, RALA's hydrophobic and hydrophilic regions facilitate interaction with the lipid bilayers, enabling transport of DNA across cellular membranes, endosomal disruption enabling transport of DNA to the nucleus. We have previously reported RALA's ability to evoke reporter transgene expression in vitro and in vivo [23] [24] .
An emerging strategy to intramuscular vaccination is to target the APC population residing in the dermis via different delivery methods such as electroporation, tattooing, or microneedle (MN) arrays. The advantages of MN technology include pain free administration, simplicity of use, lack of needle stick injury, patient compliance and low manufacturing costs 25 . MNs are designed to painlessly breach the skin's stratum corneum (SC) barrier and dissolve upon contact with the skin's interstitial fluid to release the cargo in the needle tips 26, 27 . Herein we build upon the delivery of DNA from this system 28 and report for the first time on a functional HPV-16 E6/E7 DNA vaccine candidate. In this investigation RALA-E6/E7 NPs were loaded into soluble MN arrays, and we demonstrate how effective this unique technology platform is compared to injectable systems in vivo.
Methods

Preparation of RALA-E6/E7 nanoparticles
The RALA peptide (Biomatik, USA) was supplied as a desalted lyophilized powder, and reconstituted as described previously 23 . DNA encoding the HPV-16 E6 and E7 antigens was purchased from Addgene (USA). The expression vector p1321 vector contained the genes for HPV16 E6, or E7 or E6/E7, the β-actin promoter and an ampicillin selective marker. RALA-E6/E7 NPs were prepared at N:P ratios (the molar ratio of positively charged nitrogen atoms in the peptide to negatively charged phosphates in the pDNA backbone) ranging from 1 to 12 by adding appropriate volumes of peptide solution to 1 μg pDNA. RALA-E6/E7 NPs were incubated at 19°C for 30 min to allow the formation of the NPs.
DNA neutralisation assay
RALA-E6/E7 at N:P ratios 0.25-12 were electrophoresed through a 1% agarose gel (Life Technologies, UK) with Tris acetate running buffer at 80 V for 60 min, and gels were visualized using a Multispectrum Bioimaging System (UVP, UK).
Particle size and zeta potential analysis
RALA-E6/E7 NPs were prepared at N:P ratios 2-12. The particle size and zeta potential was measured using a Nano ZS Zetasizer and DTS software (Malvern Instruments, UK) at 25 o C.
Variations included size from 4-37 o C and storage of NPs at RT up to 1 month. Each measurement (n=3) had 15 sub measurements.
Serum stability study
RALA-E6/E7 NPs were incubated for up to 6 h at 37°C in 10% fetal calf serum. Subsequently, Proteinase K (Sigma-Aldrich, UK) was added (1 mg/ml) to decomplex the pDNA from RALA and samples were electrophoresed.
Heparin stability study
DNA was labelled with Quant-iT™ PicoGreen® dsDNA reagent (Life Technologies, UK).
Heparin sulfate (Sigma, UK) (10-20 U/mL) was added to the NPs and the dissociation properties of the NPs were measured via fluorescence (FLUOstar OPTIMA; BMG LABTECH, USA) with an excitation wavelength of 480 nm and a detection wavelength of 520 nm.
Transmission electron microscopy (TEM)
RALA-E6/E7 NPs were prepared at a N:P ratio of 10 and loaded onto a Formvar/Carbon mesh grid (Agar Scientific, UK). The grid was dried overnight and stained for 5 min with 5%
aqueous uranyl acetate at 19°C. The grid was imaged using a JEOL 100CXII transmission electron microscope at an accelerating voltage of 80 kV.
Encapsulation assay
RALA-E6/E7 NPs were prepared and Quant-iT™ PicoGreen® Reagent (Life Technologies, UK)
was added to each sample. The percentage encapsulation was calculated relative to naked DNA controls. Sample fluorescence was analyzed as per 2.7.
In vitro transfections
NCTC-929 fibroblast cells (ATCC) were seeded, conditioned for 2 h in Opti-MEM (Gibco, UK), and probed with HPV-16 E6 and HVP-16 E7 antibodies (Abcam; UK). GAPDH was used as a loading control (Sigma; UK). Levels of protein expression were assessed using an Immobilon western detection kit (Millipore; UK). X-ray films were scanned using benchtop UV transilluminators (UVP Products Ltd) and density was calculated using Image J (http://rsbweb.nih.gov/ij/) incorporating correction of loading controls.
Fabrication of polymeric MN arrays
RALA-E6/E7 loaded MNs were prepared using the micro-moulding process illustrated in Fig.   4a . A 40% stock solution of PVP (360 kDa) (Sigma; UK) was prepared 50:50 with NP solution.
25 mg of the polymeric gel containing the NPs was weighed into the moulds and centrifuged to ensure the MN cavities were filled. A further 0.5 g of 20% PVP polymer was added to the moulds to form the baseplate to which the MNs are attached and centrifuged again. The arrays were left to dry at room temperature, and after 48 h, were manually released from the moulds and the polymeric sidewalls removed using a heated scalpel. Each MN array contained 361 (19x19) needles 600 μm high with base width of 300 μm and 300 μm interspacing.
Measurement of MN height reduction
To determine the axial force required for mechanical fracture of the MNs, the TA-XT2 texture analyser (Stable Microsystems, UK) was employed. MN arrays were attached to the moveable cylindrical probe of the texture analyser. An axial compression load of 45 N was applied to the polymeric MN arrays 29 . The height of the MNs was measured using a digital microscope (GE-5 USB) at 180x magnification.
Optical coherence tomography (OCT)
Neonatal full thickness porcine skin was prepared and equilibrated in PBS for 30 min at 37°C
to restore conditions resembling the in vivo state. The skin was then placed onto a sheet of dental wax for support with the SC side facing towards the environment. Manual application using the thumb for 30 sec was applied. Images were taken every 5 min to monitor the MNs dissolution profile. Depth of insertion of the MNs into the skin was determined using Image J software.
Measurement of MN Stability
The MN/RALA-E6/E7 vaccine was packed in air tight packing film in temperature controlled environments of 4.0 ± 1.0 °C, RT (20.0 ± 1.0 °C), and 37 ± 1.0 °C. After 28 days, MNs were dissolved in OptiMEM serum free media for 2 h and NCTC-929 cells were transfected (2.16).
Cell viability analysis
NCTC-929 cells were seeded for 24 h prior to the assay. Media were supplemented with 5, 10 or 20 mg/mL of 20% polymer (PVP) and incubated for 24 h. 10% MTS reagent (Promega, UK) was added to the cell medium and incubated for a further 2 h. Absorbance was measured at 450 nm on an EL808 96-well plate reader (BioTek Instruments Inc, UK).
Clonogenic Assay
24 h post transfection, NCTC-929 cells were plated at a density of 200 and 500 cells per well. Plates were then incubated for 14 days at 37 o C in 5% CO2/95% air and then colonies were fixed and stained with 0.4% crystal violet in 70% methanol and counted manually.
Quantification of DNA cargo delivered in vivo
NP-loaded MNs were applied to the dorsal surface of C57BL/6 mice ears (Charles River, UK) for 5 min, followed by removal of the array and quantification of the DNA remaining in the array using Quant-iT™ PicoGreen ® dsDNA reagent (Life Technologies, UK). The remaining array was dissolved in 5 mL Tris buffer (10 mM) for 1 h and 50 μL of 1 mg/mL Proteinase K was subsequently added and samples incubated at 37°C for 1 h. Sample fluorescence was analyzed as per 2.7.
Immunization of mice
The experimental protocols were compliant with the UK Scientific Act of 1986, project license 2794 and were approved by QUB ethics committee. C57BL/6 mice were immunized with approximately 50 μg of either naked DNA (HPV-16 E6E7) or RALA-E6/E7 NPs by either I.M. or MN application on mice ears. Vaccination was followed by a 2 nd and 3 rd booster immunizations every 2 weeks. MN arrays laden with NPs or DNA were manually inserted onto the dorsal side of both ears. The MNs were held in place for at least 5 min, secured in place using surgical adhesive tape, and then removed 24 h following application.
ELISA for detecting anti-E6/E7 antibodies
An indirect ELISA was carried out after the 2 nd and 3 rd boosts to determine E6/E7 specific IgG antibodies in mice sera. A 96 well plate was coated with 100 µl of purified HPV-16 E7/E6 peptides (Proimmune, UK) at 0.5 mg/ml and incubated at 4°C overnight. After washing the serum samples diluted in PBS (1:100) were added to the ELISA wells. The plate was incubated with a 1:2000 dilution of a goat anti-mouse IgG HRP-conjugated antibody (Sigma, UK) at RT for 1 h. An enzyme substrate (OPD, Sigma) was added for colour development and
Immunoreactivity was detected with an ELISA plate reader at 450 nm. Quantification of IgG was performed using an Easy Titer IgG assay kit (Thermo scientific, UK).
Cytotoxicity Assay
Following the third immunization, the spleen from each mouse was aseptically removed, In vitro radiation experiments were performed using a 160 kVp x-ray source (Faxitron X-ray, USA) with a 0.8 mm filter. Viable T cells were seeded with nonirradiated TC-1 cells in the ratios of 5:1 and 10:1, respectively, in an assay medium (1% BSA medium) in triplicate at 37°C for 5 h in 96-well plates. After 5 h, the supernatant of each sample was collected and TC-1 cytotoxicity was measured using a LDH cytotoxicity detection kit (Roche, UK).
Interferon-ɣ assay
After the third immunization, spleens were removed and T cells (used as the effecter cells)
were co-cultured at a ratio of 10:1 with irradiated TC-1 cells (10 4 per well) (used as the target cells), with 20 units of interleukin-2 (Peprotech, UK) in 24-well plates (Corning) at 37°C for 4 days. The supernatant (100 µl) of each sample was taken after removing any debris by centrifugation. Interferon-ɣ was detected using Interferon-ɣ ELISA kit (Peprotech, UK).
Tumour prophylactic assay
C57BL/6 mice (n=9 per group) were immunized as 2.19. One week after the last vaccination, mice were challenged with 1X10 5 TC-1 cells/mouse in PBS implanted i.d. on the rear dorsum.
The mice were monitored for evidence of tumour growth by palpation and measurement three times a week. 
Tumour challenge assay
Statistical analysis
All experiments has at least three independent replicates, and results are expressed as mean ± standard error (SE). Significance of differences was calculated using the two-tailed unpaired t-test with a p value of ≤ 0.05 considered significant. Statistical analyses of the survival curves were calculated using the log rank (Mantel-Cox) test with a p value of ≤ 0.05 considered significant. Statistical analyses were performed using Prism 5.0 (GraphPad Software; CA).
Results
Characterization and stability of RALA-E6/E7 NPs
Results indicated that the RALA-E6/E7 NPs were formed from N:P 1 onwards; RALA prevented electrophoretic migration of DNA through the gel (Fig. 1a) . (Fig. 1b) . TEM imaging at N:P 10 also revealed a core radius of NPs of approximately 70.9 nm (Fig. 1c) . Encapsulation values of >90% from N:P 4 upwards indicated efficient complexation (Fig. 1d) .
RALA-E6/E7 NPs remained stable at room temperature for up to 30 days and also over a range of temperatures (4-37 o C) (Fig. 2a & b) . Further investigations revealed that RALA preserved the integrity of the E6/E7 DNA in the presence of serum and after exposure to heparin ( Fig. 2c & d) . This confirms that the NPs could remain intact in the presence of simulated biological fluids.
In vitro gene expression with RALA-E6/E7 NPs
RALA-E6/E7 NPs successfully transfected NCTC-929 cells as demonstrated by over expression of both HPV-16 E6 and HPV-16 E7 antigens compared to untreated cells (Fig. 3a) . Toxicity of RALA is considerably reduced at 8.9% compared to commercially available agents such as Lipofectamine 2000 (25.6%) and PEI (70%) (Fig. 3b) .
The RALA-E6/E7 NPs do not compromise the PVP matrix
A single MN array contains 361 projections (Fig. 4a) , resulting in approximately 5 mg of 20% PVP. Results indicated that 20% PVP caused no significant cellular toxicity. Following exposure to the highest concentration (20 mg/mL) of PVP for 24 h, the % cell viability was 87.5% compared to untreated cells (p= 0.1597, using a one-tailed, unpaired t-test).
Morphologically, 20 mg/ml-treated cells did not appear to differ from control cells (Fig. 4b) .
Axial fracture force tests determined the mechanical strength of the PVP polymeric MNs.
Using manual force, a penetration depth of 90% of needle length was achieved, and the needles were not broken or deformed by the process (Fig. 4c) . Importantly, MNs that were loaded with RALA/E6-E7 NPs were still able to penetrate the skin effectively, displaying similar insertion mechanics to 'empty' MNs (20% PVP only). Furthermore, after evaluation of in situ dissolution kinetics of the MNs, it was found that by 15 min, MNs had both lost their needle profile and efficiently dissolved within the skin layers (Fig. 4c) . 
RALA-E6/E7 NP release and functionality following incorporation in PVP matrix
NCTC-929 cells transfected with RALA-E6/E7 NPs liberated from the PVP MN matrix
expressed the viral proteins, yet naked E6/E7 DNA released from the PVP matrix was unable to evoke protein expression (Fig. 5a ) indicating that RALA is necessary for the functionality of the E6/E7 DNA within the PVP matrix. Furthermore, PVP did not compromise functionality of the NPs after 28 days storage with a significant increase in HPV-16 E6/E7 protein expression compared to untreated cells (Fig 5b) .
For release experiments in vivo, MN arrays were fabricated to contain 36 µg total DNA;
however not the entire DNA will be present in the final MN array. Of the 36 µg total DNA initially incorporated into MN arrays, 30.2 ± 1.29 µg could be detected upon re-dissolution of the arrays; of that, 20.7 µg was present in the arrays following removal of excess sidewalls. For this reason, we therefore determined 20.7 µg to be deliverable using our MN array. Following a 5 min application to mouse ears, MN arrays were found to retain 9.5 µg DNA, indicating that 11.4 µg had been delivered; additionally, following a 24 h application procedure, only 1.9 µg DNA was retained in the arrays, indicating that 91% of the was delivered during a 24 h application (Fig. 5b) .
MN/RALA-E6/E7 evokes a consistent humoral and cell-mediated immune response
Following immunization (Fig. 6a) , it was shown that the concentration of antibodies from the NP groups (either I.M. or MN) was 2x that of the control group (Fig. 6b) . These results suggest DNA vaccination using our MN-NP system elicits a robust antigen-specific humoral immune response, facilitating immunogenic memory at levels comparable, and even superior, to those observed following I.M. injections.
Cytotoxicity and interferon-γ assays were carried out to test the immune response generated by the killing of the HPV-16 oncogenic antigen expressing cells (TC-1) by the E6/E7
plasmid. MN/RALA-E6/E7-vaccinated mice evoked a two-fold higher TC-1 cytotoxicity than control mice. Additionally the cytotoxicity was greater in MN/RALA-E6/E7-vaccinated mice than in any other treatment group (Fig. 7a) , indicating a robust immune response from MN/RALA-E6/E7 immunization.
The IFN-γ release assay demonstrates that when primed T cell-enriched splenocytes were cultured without TC-1 cells, the amount of interferon-γ secreted was almost undetectable (Fig. 7b) . However, when the primed T cell-enriched splenocytes were co-cultured with TC-1 cells, there was an increase in the amount of IFN-γ released by the T cell-enriched splenocytes; the most impressive release of IFN-γ was from the MN/RALA-E6/E7-vaccinated mice, which was significantly higher than the degree of IFN-γ released by T cells from naïve mice (p= 0.035 for mice vaccinated with MN/RALA-E6/E7 compared to controls). This is indicative of a cytotoxic T cell-mediated immune response.
MN/RALA-E6/E7 vaccination prevents the uptake of tumours and slows the growth of established tumours
In the prophylactic study, tumours were palpable at seven days post-challenge (i. In the therapeutic arm of the study, we determined that MN/RALA-E6/E7 vaccination of mice with pre-existing tumours caused complete regression of tumours in 2/9 mice (2 mice were censored because of other causes but their GMDs were ˂ 12 mm). Whereas when mice were vaccinated using RALA-E6/E7 by the I.M. route or naked DNA in MN, complete regression was observed in only 11% of mice (1/9). None of the other vaccination strategies significantly altered tumour growth kinetics/mouse survival (Fig. 8b) . Furthermore, a clear difference in the tumour volume was found for the tumour-bearing mice that followed MN/RALA-E6/E7 vs other vaccination strategies (p= 0.004 two-tailed unpaired t-test 
Discussion
In this study, we validated a new system for the delivery of a HPV DNA therapeutic vaccine, which overcomes both intracellular and extracellular barriers using RALA/E6-E7 NPs, loaded in a PVP-based MN platform. Immune responses can be augmented by utilising delivery systems to protect the DNA cargo and facilitate delivery to APCs 30 . For optimal cell uptake, NPs should be less than 150 nm in diameter, have sufficient cationic charge to prevent aggregation in order to bind to the negatively charged cell membrane 23 . In this study, RALA conferred ideal size and charge characteristics on the E6-E7 DNA to facilitate efficient cellular uptake and antigen expression.
The increased incidence of APCs in the dermal region has garnered interest in transcutaneous DNA vaccine delivery. Lower numbers of APCs are associated with I.M.
vaccination and so efficient drainage to lymph nodes is required for antigen presentation 31 .
A number of in vivo studies have demonstrated that MN immunization elicits an efficient immune response 32, 33 . Naked DNA 34 , influenza 35 and HPV virus-like particles (VLP) 36 , have elicited both B-and T-cell immune responses after administration to the skin using MNs.
Rapid dissolution of MN arrays in the skin could be advantageous for vaccination and PVP can be safely excreted through the kidneys within a few days 32, 37 . In this study the MNs could penetrate skin effectively and more importantly, MN-NP arrays retained functionality following extended storage conditions. Results revealed efficient transfection with RALA/E6-E7 NPs with no transfection with naked HPV-16 E6-E7 into the polymer suggesting that the RALA is essential to protect the DNA in polymeric MN system. Similar observations have been reported where poly(lactic-co-glycolic acid) (PLGA) dissolving MNs adversely affected the stability of naked pDNA, with a subsequent loss of bioactivity 38 .
It has been reported that a low dose of HPV16 PsV-encapsidated DNA (0.3 μg) incorporated
into MNs effectively produced neutralizing antibody response against HPV 39 . Therefore, the quantity of DNA (10 μg) that we can deliver via the ear pinna should be sufficient to evoke an immune response. The ear pinna exhibits two layers of epidermis and dermis, separated by cartilage, thereby doubling the amount of professional APCs, which after appropriate activation, migrate to one major pinna draining lymph node, eliciting rapid immune response induction 40 . Indeed humoral and cytotoxic T cell-mediated immune responses after intra ear pinna (i.e.) DNA vaccination have been ~10 times stronger than I.M. MN/RALA-E6/E7-vaccinated mice evoked a two-fold higher TC-1 cytotoxicity than control mice, and a significant target-cell lysis was observed even at low effector-to-target ratios.
Primed T cells can respond quickly and strongly when they come in contact with antigens previously encountered, leading to large amount of interferon-γ secretion shown that MN vaccination rapidly induces specific tumour infiltrating CD8+ T cells [43] [44] . In both arms of the study, administration of E6/E7 peptides had no effect on tumour survival.
Poor immunogenicity of peptide-based vaccines is not uncommon as they are heavily affected by the restriction of MHC 45 . However it is also recognized that DNA vaccines can have limited immunogenicity in animal models 46 . Therefore future studies could focus on the co-administration of adjuvants, such as the C-terminal fragment of glycoprotein 96 (gp96), to stimulate E7-specific immune responses 47 . The further advantage of our nano-technology is that a bi or trivalent strategy can be incorporated into the MN patch.
In this study, we have demonstrated successful cutaneous delivery of a DNA vaccine via in vivo delivery of NPs, resulting in a robust antigen-specific immune response. Furthermore, prophylactic vaccination using NP-loaded MNs protected against cervical tumour development, and delayed the progression of established cervical cancer xenografts. Such MN-based DNA vaccines do not require cold-chain storage thus reducing costs, and ultimately should improve patient compliance. The licensing of four DNA vaccines in the veterinary medicine field 48 provides optimism that DNA vaccines may soon be approved for applications in humans 49, 50 , and this study should represent an important breakthrough technology for antigen-associated cancers. Following each immunization, blood serum was isolated and IgG levels measured via ELISA.
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